(2)
Q1 2021 net sales rise 52% (48% CER) to $567.2 million, exceeds outlook for at least 45% CER growth; adj. EPS up 94% to $0.66 ($0.65 CER), exceeds outlook for ~$0.60-0.62 CER
16% CER growth to $364 million from non-COVID product groups, represent 64% of total sales, while COVID-19 product group sales rise 186% CER to $203 million
Q1 2021 operating cash flow rises over 700% to $128.6 million, free cash flow of $82.3 million
Reaffirming full-year 2021 outlook for ~18-20% CER net sales growth and ~$2.42-2.46 CER adjusted diluted EPS
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced strong results of operations for the first quarter of 2021, exceeding the goals for net sales and adjusted earnings per share.
QIAGEN N.V.: QIAGEN Announces EZ2 Connect Instrument Line for Automated Sample Processing in Research, Forensics and Diagnostics
Building on the success of EZ1 technology, three versions offer application area tailored value
Integration with QIAsphere digital infrastructure allows for optimized lab productivity
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the upcoming launch of the EZ2 Connect product line, a next-level automated sample-processing platform whose simplicity, flexibility and speed will benefit biomedical research, forensics and clinical diagnostics.
The EZ2 Connect instruments use pre-filled cartridges and magnetic bead technology to process up to 24 samples in parallel in as little as 20 minutes, ensuring process safety and efficiency of nucleic acid extraction. The new platform builds on QIAGEN s groundbreaking EZ1 instrument line, which set new standards in the automation of sample preparation and sample-data management and has seen
Nachricht vom 27.04.2021 | 17:40
Epigenomics AG decides to increase share capital through rights issue with subscription rights of existing shareholders
DGAP-News: Epigenomics AG / Key word(s): Capital Increase
27.04.2021 / 17:40
The issuer is solely responsible for the content of this announcement.
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, JAPAN, AUSTRALIA AND SOUTH AFRICA.
Press release
Epigenomics AG decides to increase share capital through rights issue with subscription rights of existing shareholders
Berlin, 27 April 2021 - On 27 April 2021, the Executive Board of Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY; the company ) resolved, with approval of the Supervisory Board, to increase the company s share capital through a rights issue using the Authorized Capital 2020/II. The share capital shall be increased from currently EUR 9,852,690.00 by up to EUR 1,970,538.00 to up
Epigenomics AG decides to increase share capital through rights issue with subscription rights of existing shareholders
Tel +49 (0) 30 24345 0, Fax +49 (0) 30 24345 555, e-mail: contact@epigenomics.com
Investor Relations
Important Notice
This publication does not constitute or form part of, and should not be construed as an offer or an invitation to sell, or issue or the solicitation of any offer to buy or subscribe for, any securities. The shares will be solely offered on the basis of the published subscription offer. This publication does, in particular, not constitute an offer to sell or a solicitation of an offer to purchase any securities in the United States. The securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the Securities Act ) or the laws of any state within the U.S., and may not be offered or sold in the United States or to or for the account or benefit of U.S. perso
Epigenomics AG decides to increase share capital through rights issue with subscription rights of existing shareholders direktbroker.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from direktbroker.de Daily Mail and Mail on Sunday newspapers.